💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇻🇳 Tiếng Việt

Exagamglogene Autotemcel

CHEMBL5095474 Phase 4 Đã phê duyệt Gene
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This gene editing therapy uses CRISPR technology on a patient's own stem cells to reactivate fetal hemoglobin production, providing a potentially curative treatment for sickle cell disease and transfusion-dependent beta-thalassemia. The edited cells are returned to the patient after conditioning.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This gene editing therapy uses CRISPR technology on a patient's own stem cells to reactivate fetal hemoglobin production, providing a potentially curative treatment for sickle cell disease and transfusion-dependent beta-thalassemia. The edited cells are returned to the patient after conditioning.

Yes, Exagamglogene Autotemcel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095474. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.